139 related articles for article (PubMed ID: 26553688)
1. Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.
Price GA; Hollander AM; Plikaytis BD; Mocca BT; Carlone G; Findlow H; Borrow R; Sow SO; Diallo A; Idoko OT; Enwere GC; Elie C; Preziosi MP; Kulkarni PS; Bash MC
Clin Infect Dis; 2015 Nov; 61 Suppl 5():S554-62. PubMed ID: 26553688
[TBL] [Abstract][Full Text] [Related]
2. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults.
Findlow H; Plikaytis BD; Aase A; Bash MC; Chadha H; Elie C; Laher G; Martinez J; Herstad T; Newton E; Viviani S; Papaspyridis C; Kulkarni P; Wilding M; Preziosi MP; Marchetti E; Hassan-King M; La Force FM; Carlone G; Borrow R
Clin Vaccine Immunol; 2009 Jul; 16(7):969-77. PubMed ID: 19474264
[TBL] [Abstract][Full Text] [Related]
3. Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers.
Bash MC; Lynn F; Mocca B; Borrow R; Findlow H; Hassan-King M; Preziosi MP; Idoko O; Sow S; Kulkarni P; Laforce FM
Clin Vaccine Immunol; 2014 May; 21(5):755-61. PubMed ID: 24671551
[TBL] [Abstract][Full Text] [Related]
4. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
[TBL] [Abstract][Full Text] [Related]
5. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.
Gill CJ; Ram S; Welsch JA; Detora L; Anemona A
Vaccine; 2011 Dec; 30(1):29-34. PubMed ID: 22075087
[TBL] [Abstract][Full Text] [Related]
6. Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
Diallo A; Sow SO; Idoko OT; Hirve S; Findlow H; Preziosi MP; Elie C; Kulkarni PS; Parulekar V; Diarra B; Cheick Haidara F; Diallo F; Tapia M; Akinsola AK; Adegbola RA; Bavdekar A; Juvekar S; Chaumont J; Martellet L; Marchetti E; LaForce MF; Plikaytis BD; Enwere GC; Tang Y; Borrow R; Carlone G; Viviani S
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S521-30. PubMed ID: 26553684
[TBL] [Abstract][Full Text] [Related]
7. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
9. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.
Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686
[TBL] [Abstract][Full Text] [Related]
10. Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.
Holme D; Findlow H; Sow SO; Idoko OT; Preziosi MP; Carlone G; Plikaytis BD; Borrow R
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S563-9. PubMed ID: 26553689
[TBL] [Abstract][Full Text] [Related]
11. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2016; 12(1):132-9. PubMed ID: 26575983
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.
Sow SO; Okoko BJ; Diallo A; Viviani S; Borrow R; Carlone G; Tapia M; Akinsola AK; Arduin P; Findlow H; Elie C; Haidara FC; Adegbola RA; Diop D; Parulekar V; Chaumont J; Martellet L; Diallo F; Idoko OT; Tang Y; Plikaytis BD; Kulkarni PS; Marchetti E; LaForce FM; Preziosi MP
N Engl J Med; 2011 Jun; 364(24):2293-304. PubMed ID: 21675889
[TBL] [Abstract][Full Text] [Related]
13. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
14. Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials.
White M; Idoko O; Sow S; Diallo A; Kampmann B; Borrow R; Trotter C
Lancet Infect Dis; 2019 Mar; 19(3):327-336. PubMed ID: 30745277
[TBL] [Abstract][Full Text] [Related]
15. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.
Borrow R; Andrews N; Goldblatt D; Miller E
Infect Immun; 2001 Mar; 69(3):1568-73. PubMed ID: 11179328
[TBL] [Abstract][Full Text] [Related]
16. Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.
Findlow H; Sow S; Borrow R; Tapia M; Haidara FC; Akinsola AK; Idoko OT; Diallo F; Adegbola R; Tang Y; Parulekar V; Chadha H; Mabey L; Holme D; Townsend K; Chaumont J; Laforce FM; Kulkarni PS; Marchetti E; Viviani S; Hassan-King M; Preziosi MP
Clin Vaccine Immunol; 2011 Sep; 18(9):1492-6. PubMed ID: 21752951
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.
Vesikari T; Forstén A; Boutriau D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2012 Dec; 8(12):1892-903. PubMed ID: 23032159
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.
Hirve S; Bavdekar A; Pandit A; Juvekar S; Patil M; Preziosi MP; Tang Y; Marchetti E; Martellet L; Findlow H; Elie C; Parulekar V; Plikaytis B; Borrow R; Carlone G; Kulkarni PS; Goel A; Suresh K; Beri S; Kapre S; Jadhav S; Preaud JM; Viviani S; LaForce FM
Vaccine; 2012 Oct; 30(45):6456-60. PubMed ID: 22898557
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
20. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
